GFAP and dementia: Despite p‐tau181 having similar performance as observed in bPRIDE at the AD dementia stage (AUC p‐tau181 validation: 0.93 [0.85–1.00], bPRIDE: 0.95 [0.90–1.00]), plasma GFAP was the best biomarker discriminating any stage of the AD continuum compared to controls and comparing AD to FTD in the validation cohort 1 (AUC: 0.96 [0.9–1.00], Figure S2).